Demis Hassabis's Isomorphic Labs announces Series B investment round with $2.1B in new funding
Summary
Isomorphic Labs, an AI-driven drug discovery company founded by Demis Hassabis, announced a $2.1 billion Series B funding round led by Thrive Capital to scale its business and advance its AI drug design engine, IsoDDE.
View Cached Full Text
Cached at: 05/12/26, 04:47 PM
Similar Articles
@ecommartinez: BREAKING NEWS: The co-founder of Google DeepMind has just announced $2.1 billion to cure all diseases. Demis Hassabis h…
Demis Hassabis, co-founder of Google DeepMind, announces $2.1 billion in funding for Isomorphic Labs to use AI to cure all diseases by accelerating drug discovery.
@itsolelehmann: Demis Hassabis says he can cure every disease in 10 years. Most people roll their eyes when they hear this, but I don't…
Demis Hassabis claims AI can cure all diseases within 10 years, backed by a $2.1B funding round for Isomorphic Labs to accelerate AI-driven drug discovery and personalized medicine.
@edels0n: $65B private round More than double the size of the largest IPO ever
Anthropic announces $65 billion Series H funding round at $965 billion post-money valuation, led by Altimeter Capital, Dragoneer, Greenoaks, and Sequoia, to advance AI research and expand capacity for Claude.
OpenAI-backed Thrive Holdings raises $2B to bring AI to the enterprise
Thrive Holdings raised $2B at a $12B valuation to expand its AI implementation business into new verticals like physical infrastructure, backed by SoftBank and others, with OpenAI as a strategic partner.
@steph_palazzolo: The CEO of popular AI assistant Instinct has told investors he’s looking to raise $1b in new funding. That could imply …
The CEO of AI assistant company Instinct is seeking $1 billion in funding, potentially indicating a $10 billion valuation, which is a fourfold increase from last month.